Nivolumab

Phase 2Terminated

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Lung Cancer, Nonsmall Cell

Conditions

Lung Cancer, Nonsmall Cell, Lung Cancer Stage III

Trial Timeline

Dec 13, 2023 → Jul 5, 2024

NCT ID

NCT06003075

About Nivolumab

Nivolumab is a phase 2 stage product being developed by Bristol Myers Squibb for Lung Cancer, Nonsmall Cell. The current trial status is terminated. This product is registered under clinical trial identifier NCT06003075. Target conditions include Lung Cancer, Nonsmall Cell, Lung Cancer Stage III.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03126643	Pre-clinical	Completed	—	—	Pediatric Cancer
NCT02475382	Pre-clinical	Completed	—	—	Squamous Non-Small Cell Lung Cancer
NCT06523621	Phase 2	Recruiting	Feb 28, 2025	Nov 1, 2027	Multiple Myeloma
NCT06499298	Pre-clinical	Completed	Dec 3, 2024	Apr 16, 2025	Esophageal Cancer
NCT06735781	Pre-clinical	Completed	Sep 5, 2024	Oct 1, 2024	Non-small Cell Lung Cancer (NSCLC)
NCT06421311	Pre-clinical	Terminated	Jul 30, 2024	Apr 4, 2025	Urothelial Carcinoma
NCT06452329	Pre-clinical	Completed	Feb 28, 2024	Jul 29, 2025	Gastric Cancer
NCT06003075	Phase 2	Terminated	Dec 13, 2023	Jul 5, 2024	Lung Cancer, Nonsmall Cell
NCT06361576	Pre-clinical	Completed	Sep 5, 2023	Jan 25, 2024	Upper Gastrointestinal Cancer
NCT06361563	Pre-clinical	Completed	Sep 5, 2023	Jan 25, 2024	Upper Gastrointestinal Cancer
NCT05068609	Pre-clinical	Completed	Aug 13, 2020	Oct 18, 2021	Squamous Cell Carcinoma of the Head and Neck
NCT04936399	Pre-clinical	Completed	Jun 25, 2020	Dec 3, 2021	Esophageal Squamous Cell Carcinoma
NCT04205409	Phase 2	Active	Jun 5, 2020	Aug 1, 2029	Recurrent Chronic Lymphocytic Leukemia
NCT04401774	Phase 2	Completed	May 22, 2020	Jan 22, 2026	Primary Central Nervous System Lymphoma (PCNSL)
NCT04361058	Phase 1	Withdrawn	Apr 13, 2020	Apr 20, 2021	Leukemia, Myeloid, Acute
NCT04022980	Phase 1	Completed	Mar 31, 2020	Dec 22, 2025	Brain and Nervous System
NCT04019964	Phase 2	Completed	Jan 13, 2020	Jul 3, 2025	Prostate Cancer
NCT04146324	Pre-clinical	Completed	Dec 12, 2019	May 31, 2024	Melanoma
NCT04099251	Phase 3	Active	Oct 28, 2019	Jun 29, 2027	Melanoma
NCT03981146	Phase 2	Active	Aug 28, 2019	Oct 1, 2024	Colorectal Cancer

Competing Products

20 competing products in Lung Cancer, Nonsmall Cell

See all competitors

Product	Company	Stage	Hype Score
BBP-398 with nivolumab	BridgeBio Pharma	Phase 1	30
Pemetrexed + Carboplatin	Eli Lilly	Phase 3	77
Necitumumab + Gemcitabine + Carboplatin	Eli Lilly	Phase 2	52
Selpercatinib	Eli Lilly	Pre-clinical	23
Pemetrexed + Cisplatin + Placebo + Pemetrexed	Eli Lilly	Phase 3	77
NBTXR3	Nanobiotix	Phase 1/2	36
Pemetrexed	Eli Lilly	Pre-clinical	23
pemetrexed + erlotinib	Eli Lilly	Phase 2	52
Necitumumab-Gemcitabine-Cisplatin	Eli Lilly	Phase 2	52
LY3295668 Erbumine	Eli Lilly	Phase 1	33
FYB206 + FYB206 + Keytruda	Formycon AG	Phase 3	69
6-Thio-2'-Deoxyguanosine + Cemiplimab	MAIA Biotechnology	Phase 2	44
6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone	MAIA Biotechnology	Phase 3	69
pemetrexed + cisplatin	Eli Lilly	Phase 2	52
gemcitabine + carboplatin + cisplatin	Eli Lilly	Phase 2	52
Cetuximab	Eli Lilly	Phase 1	33
pemetrexed + docetaxel	Eli Lilly	Phase 3	77
enzastaurin + pemetrexed + docetaxel + carboplatin	Eli Lilly	Phase 2	52
PemCarbo + Pem only	Eli Lilly	Phase 3	77
TNG456 + abemaciclib	Eli Lilly	Phase 1/2	41

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved